The use of pimecrolimus cream 1% in the treatment of facial psoriasis

E. Frigerio, M. Taglioni, C. Franchi, C. Garutti, S. Spadino, A. Altomare, G. F. Altomare

Research output: Contribution to journalArticle

Abstract

Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.

Original languageEnglish
Pages (from-to)415-419
Number of pages5
JournalGiornale Italiano di Dermatologia e Venereologia
Volume141
Issue number4
Publication statusPublished - 2006

Fingerprint

Psoriasis
Therapeutics
Erythema
Pharmaceutical Preparations
pimecrolimus

Keywords

  • Face
  • Pimecrolimus
  • Psoriasis, drug therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Frigerio, E., Taglioni, M., Franchi, C., Garutti, C., Spadino, S., Altomare, A., & Altomare, G. F. (2006). The use of pimecrolimus cream 1% in the treatment of facial psoriasis. Giornale Italiano di Dermatologia e Venereologia, 141(4), 415-419.

The use of pimecrolimus cream 1% in the treatment of facial psoriasis. / Frigerio, E.; Taglioni, M.; Franchi, C.; Garutti, C.; Spadino, S.; Altomare, A.; Altomare, G. F.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 141, No. 4, 2006, p. 415-419.

Research output: Contribution to journalArticle

Frigerio, E, Taglioni, M, Franchi, C, Garutti, C, Spadino, S, Altomare, A & Altomare, GF 2006, 'The use of pimecrolimus cream 1% in the treatment of facial psoriasis', Giornale Italiano di Dermatologia e Venereologia, vol. 141, no. 4, pp. 415-419.
Frigerio E, Taglioni M, Franchi C, Garutti C, Spadino S, Altomare A et al. The use of pimecrolimus cream 1% in the treatment of facial psoriasis. Giornale Italiano di Dermatologia e Venereologia. 2006;141(4):415-419.
Frigerio, E. ; Taglioni, M. ; Franchi, C. ; Garutti, C. ; Spadino, S. ; Altomare, A. ; Altomare, G. F. / The use of pimecrolimus cream 1% in the treatment of facial psoriasis. In: Giornale Italiano di Dermatologia e Venereologia. 2006 ; Vol. 141, No. 4. pp. 415-419.
@article{254e397fbc694799a0483edd000f39e8,
title = "The use of pimecrolimus cream 1{\%} in the treatment of facial psoriasis",
abstract = "Aim. To evaluate the efficacy of pimecrolimus cream 1{\%} in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1{\%}. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5{\%} of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5{\%} of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1{\%} has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.",
keywords = "Face, Pimecrolimus, Psoriasis, drug therapy",
author = "E. Frigerio and M. Taglioni and C. Franchi and C. Garutti and S. Spadino and A. Altomare and Altomare, {G. F.}",
year = "2006",
language = "English",
volume = "141",
pages = "415--419",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - The use of pimecrolimus cream 1% in the treatment of facial psoriasis

AU - Frigerio, E.

AU - Taglioni, M.

AU - Franchi, C.

AU - Garutti, C.

AU - Spadino, S.

AU - Altomare, A.

AU - Altomare, G. F.

PY - 2006

Y1 - 2006

N2 - Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.

AB - Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.

KW - Face

KW - Pimecrolimus

KW - Psoriasis, drug therapy

UR - http://www.scopus.com/inward/record.url?scp=33749468546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749468546&partnerID=8YFLogxK

M3 - Article

VL - 141

SP - 415

EP - 419

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 4

ER -